<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02732873</url>
  </required_header>
  <id_info>
    <org_study_id>ORX/2016/FM02</org_study_id>
    <nct_id>NCT02732873</nct_id>
  </id_info>
  <brief_title>Porous Tissue Regenerative Silk Scaffold for Human Meniscal Cartilage Repair</brief_title>
  <acronym>REKREATE</acronym>
  <official_title>A Multicentre Study Evaluating the Treatment of Meniscal Defects With a Meniscal Repair Scaffold, FibroFix™ Meniscus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orthox Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Southmead Hospital, Bristol, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Magdeburg University Hospital, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brandenburg University Hospital, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BundeswehrKrankenhaus Ulm, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitat Autonoma de Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier du Luxembourg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Orthox Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The REKREATE project will be an international, multi-centre, non-randomised, prospective&#xD;
      single-arm pivotal study. All study patients will receive the FibroFix™ Meniscus scaffold&#xD;
      following the provision of informed consent. A study period of 1 year and extended follow up&#xD;
      period of up to 3 years is planned , to enable a thorough and complete assessment of the&#xD;
      performance of the device when implanted to replace removed or damaged meniscal tissue in&#xD;
      humans. The test article for this multi-centre study is the FibroFix™ Meniscus scaffold,&#xD;
      which has been developed for repair of defects of the meniscus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance analysis of meniscal scaffold</measure>
    <time_frame>At 12 months follow up</time_frame>
    <description>Performance will be assessed by means of recognised, validated, standardised questionnaires (IKDC, Lysholm, Tegner)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical criteria: quality of life</measure>
    <time_frame>At 12 months follow up</time_frame>
    <description>Subjective assessments using internationally validated questionnaires EQ5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of safety of meniscal scaffold - Incidence and severity of Adverse Events; incidence and severity of surgical complications</measure>
    <time_frame>At 12 months follow up</time_frame>
    <description>Incidence and severity of Adverse Events; incidence and severity of surgical complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical criteria: pain</measure>
    <time_frame>At 12 months follow up</time_frame>
    <description>At 12 months follow up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Repair of Meniscal Injury</condition>
  <arm_group>
    <arm_group_label>FibroFix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FibroFix Meniscal Scaffold</intervention_name>
    <description>FibroFix™ Meniscus scaffold is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear.</description>
    <arm_group_label>FibroFix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject (or guardian, if appropriate) has signed and dated a specific informed&#xD;
             consent form;&#xD;
&#xD;
          -  The subject is over the age of 18 and ≤55 years of age;&#xD;
&#xD;
          -  The subject is able to comply with the protocol-defined pre-operative procedures, the&#xD;
             post-operative clinical and radiographic evaluations and the recommended&#xD;
             rehabilitation regimen as determined by the Investigator;&#xD;
&#xD;
          -  The subject has a diagnosis of an MRI or arthroscopically confirmed irreparable medial&#xD;
             meniscus defect;&#xD;
&#xD;
          -  The meniscal defect should represent 25% or more of the meniscus and be amenable to&#xD;
             implantation;&#xD;
&#xD;
          -  The peripheral meniscal rim must be present;&#xD;
&#xD;
          -  The subject has a functionally intact ACL (Anterior Cruciate Ligament);&#xD;
&#xD;
          -  Haemoglobin &gt;9g/dL and platelet count &gt;100,000/mm3 prior to Day 1;&#xD;
&#xD;
          -  No contraindication to general anaesthetic;&#xD;
&#xD;
          -  Female subjects of child-bearing potential: a negative urine pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is &gt;55 years of age;&#xD;
&#xD;
          -  The subject has a functionally deficient ACL;&#xD;
&#xD;
          -  The subject has concomitant posterior cruciate ligament insufficiency of the involved&#xD;
             knee or a concomitant injury that interferes with the subject's ability to comply with&#xD;
             the recommended rehabilitation programme;&#xD;
&#xD;
          -  The subject has a diagnosis of Grade IV Outerbridge Scale degenerative cartilage&#xD;
             disease in the involved knee joint;&#xD;
&#xD;
          -  Patients demonstrating an active local or systemic infection;&#xD;
&#xD;
          -  Any condition, which in the judgment of the Investigator would preclude adequate&#xD;
             evaluation of the FibroFix™ Meniscus scaffold and clinical outcome;&#xD;
&#xD;
          -  The subject has a history of confirmed anaphylactoid reaction;&#xD;
&#xD;
          -  The subject has received local administration of any type of corticosteroid or&#xD;
             systemic administration of antineoplastic, immunostimulating, or immunosuppressive&#xD;
             agents within 180 days prior to the scheduled surgery;&#xD;
&#xD;
          -  The subject has evidence of osteonecrosis of the involved knee;&#xD;
&#xD;
          -  The subject has a medical history that includes a confirmed diagnosis of rheumatoid or&#xD;
             inflammatory arthritis, or relapsing polychondritis;&#xD;
&#xD;
          -  If female and of child-bearing potential: evidence of a positive pregnancy test or a&#xD;
             stated intention to become pregnant in the next 6-12 months;&#xD;
&#xD;
          -  Current or recent (&lt;3 months) participation in another device or drug study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ashley Blom, Professor</last_name>
    <phone>+44 (0)117 3232291</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Whitehouse Mike</last_name>
    <phone>+44 (0)117 3232291</phone>
  </overall_contact_backup>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>March 9, 2016</study_first_submitted>
  <study_first_submitted_qc>April 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2016</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

